Aardvark Therapeutics, Inc. Class Action Lawsuit
Company: Aardvark Therapeutics, Inc.
Ticker: (NASDAQ) AARD
Class Definition: All persons and entities that purchased or otherwise acquired: (a) Aardvark common stock pursuant and/or traceable to the Company’s initial public offering conducted on February 13, 2025; and/or (b) Aardvark securities between February 13, 2025 and May 14, 2026, both dates inclusive.
See If You Qualify For Monetary Reward
How to Check Whether You May Be Eligible in the Aardvark Therapeutics, Inc. Class Action
CLASS DEFINITION
All persons and entities that purchased or otherwise acquired: (a) Aardvark common stock pursuant and/or traceable to the Company’s initial public offering conducted on February 13, 2025; and/or (b) Aardvark securities between February 13, 2025 and May 14, 2026, both dates inclusive.
Allegations
The complaint filed against Aardvark Therapeutics, Inc. alleges the company made statements that were materially false and/or misleading and/or failed to disclose that: (i) ARD-101 was less safe than defendants had led investors to believe; (ii) accordingly, ARD-101’s clinical, regulatory, and commercial prospects were overstated; and (iii) as a result, the offering documents were materially false and/or misleading and failed to state information required to be stated therein.
Eligibility
To be eligible for the lawsuit, you need to have suffered a financial loss on Aardvark Therapeutics, Inc. shares that were bought or otherwise acquired during the class period noted above and/or in connection with the stock offering(s) mentioned above.
Lead Plaintiff Deadline
If you suffered a loss in Aardvark Therapeutics, Inc. during the relevant time frame, you have until October 13, 2026 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Frequently Asked Questions
- How can Aardvark Therapeutics, Inc. (NASDAQ: AARD) investors check whether their transactions may be relevant?
Investors who purchased shares of Aardvark Therapeutics, Inc. (NASDAQ: AARD) during the class period (February 13, 2025 - May 14, 2026) may submit their transaction details through this case page.
- Ensure your purchase falls within the class period
- Provide basic transaction and loss details
- Submit your information before the deadline
The lead plaintiff deadline for this case is October 13, 2026. This deadline applies only to investors seeking to serve as lead plaintiff. Class members who do not apply may still participate in any recovery without taking action before this date.
- Who is eligible for the Aardvark Therapeutics, Inc. lawsuit?
Anyone who bought shares of Aardvark Therapeutics, Inc. (NASDAQ: AARD) during February 13, 2025 - May 14, 2026 and suffered financial losses may be eligible.
- What is the lead plaintiff deadline in the Aardvark Therapeutics, Inc. case?
The lead plaintiff deadline for the Aardvark Therapeutics, Inc. lawsuit is October 13, 2026. Investors who wish to seek appointment as lead plaintiff should act quickly to avoid missing this deadline. No action is required before that date to remain an absent class member.
- What is the class period for Aardvark Therapeutics, Inc.?
The class period for Aardvark Therapeutics, Inc. (NASDAQ: AARD) is February 13, 2025 - May 14, 2026, during which investors may have been affected by alleged misconduct.
- Could I still be eligible for the Aardvark Therapeutics, Inc. lawsuit if I sold my shares?
Yes. Investors who purchased Aardvark Therapeutics, Inc. shares during February 13, 2025 - May 14, 2026 may still qualify, even if they sold their shares later.
- How much compensation can I receive from the Aardvark Therapeutics, Inc. lawsuit?
Compensation depends on the total losses and the final settlement. Eligible investors in the Aardvark Therapeutics, Inc. case may receive a portion of the recovery.
- Do I need to pay to participate in the Aardvark Therapeutics, Inc. case?
No. Most securities fraud cases are handled on a contingency basis, meaning there are generally no upfront attorney’s fees, and attorney’s fees are collected only if there is a recovery.
- Will I need to appear in court for the Aardvark Therapeutics, Inc. lawsuit?
In most cases, investors do not need to appear in court. The legal team manages the Aardvark Therapeutics, Inc. case on behalf of participants.
- What documents are required for the Aardvark Therapeutics, Inc. lawsuit?
To participate in the Aardvark Therapeutics, Inc. lawsuit, investors may need to provide transaction records, purchase dates, number of shares, and loss details.
- What happens after I submit my trade information for Aardvark Therapeutics, Inc.?
After submission, your details for the Aardvark Therapeutics, Inc. case will be reviewed, and you may be contacted regarding eligibility or next steps.
- Is this legal advice for the Aardvark Therapeutics, Inc. lawsuit?
No, this page provides information about the Aardvark Therapeutics, Inc. case and does not constitute legal advice or create an attorney-client relationship.
- Why should I act quickly on the Aardvark Therapeutics, Inc. case?
The lead plaintiff deadline for the Aardvark Therapeutics, Inc. lawsuit is October 13, 2026. Investors who wish to seek appointment as lead plaintiff must apply by that date.
EXPLORE MORE CASES
Park Ha Biological Technology Co., Ltd.
BYAH
Lead Plaintiff Deadline: September 28, 2026
Class Period: December 27, 2024 - July 8, 2025
Cogent Communications Holdings, Inc.
CCOI
Cogent Communications Holdings, Inc. (CCOI) Securities Class Action Lawsuit
Lead Plaintiff Deadline: September 21, 2026
Class Period: February 29, 2024 - May 1, 2026